You just read:

BerGenBio to Present NSCLC and AML Clinical Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019

News provided by

BerGenBio ASA

23 Apr, 2019, 06:54 BST